469 related articles for article (PubMed ID: 15824263)
1. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
[TBL] [Abstract][Full Text] [Related]
2. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
Ribaï P; Pousset F; Tanguy ML; Rivaud-Pechoux S; Le Ber I; Gasparini F; Charles P; Béraud AS; Schmitt M; Koenig M; Mallet A; Brice A; Dürr A
Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia.
Lodi R; Hart PE; Rajagopalan B; Taylor DJ; Crilley JG; Bradley JL; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Ann Neurol; 2001 May; 49(5):590-6. PubMed ID: 11357949
[TBL] [Abstract][Full Text] [Related]
4. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy.
Cooper JM; Korlipara LV; Hart PE; Bradley JL; Schapira AH
Eur J Neurol; 2008 Dec; 15(12):1371-9. PubMed ID: 19049556
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
6. Neurophysiological evaluation in children with Friedreich's ataxia.
Sival DA; du Marchie Sarvaas GJ; Brouwer OF; Uges DR; Verschuuren-Bemelmans CC; Maurits NM; Brunt ER; van der Hoeven JH
Early Hum Dev; 2009 Oct; 85(10):647-51. PubMed ID: 19775837
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
[TBL] [Abstract][Full Text] [Related]
8. Friedreich's ataxia: from disease mechanisms to therapeutic interventions.
Lodi R; Tonon C; Calabrese V; Schapira AH
Antioxid Redox Signal; 2006; 8(3-4):438-43. PubMed ID: 16677089
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
[TBL] [Abstract][Full Text] [Related]
10. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
Cooper JM; Schapira AH
Mitochondrion; 2007 Jun; 7 Suppl():S127-35. PubMed ID: 17485244
[TBL] [Abstract][Full Text] [Related]
11. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
Cooper JM; Schapira AH
Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
[TBL] [Abstract][Full Text] [Related]
12. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Seznec H; Simon D; Monassier L; Criqui-Filipe P; Gansmuller A; Rustin P; Koenig M; Puccio H
Hum Mol Genet; 2004 May; 13(10):1017-24. PubMed ID: 15028670
[TBL] [Abstract][Full Text] [Related]
13. Friedreich ataxia: the oxidative stress paradox.
Seznec H; Simon D; Bouton C; Reutenauer L; Hertzog A; Golik P; Procaccio V; Patel M; Drapier JC; Koenig M; Puccio H
Hum Mol Genet; 2005 Feb; 14(4):463-74. PubMed ID: 15615771
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose idebenone and quality of life in Friedreich ataxia.
Brandsema JF; Stephens D; Hartley J; Yoon G
Pediatr Neurol; 2010 May; 42(5):338-42. PubMed ID: 20399388
[TBL] [Abstract][Full Text] [Related]
15. Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.
Nachbauer W; Boesch S; Schneider R; Eigentler A; Wanschitz J; Poewe W; Schocke M
PLoS One; 2013; 8(7):e69229. PubMed ID: 23922695
[TBL] [Abstract][Full Text] [Related]
16. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three clinical rating scales in Friedreich ataxia (FRDA).
Bürk K; Mälzig U; Wolf S; Heck S; Dimitriadis K; Schmitz-Hübsch T; Hering S; Lindig TM; Haug V; Timmann D; Degen I; Kruse B; Dörr JM; Ratzka S; Ivo A; Schöls L; Boesch S; Klockgether T; Klopstock T; Schulz JB
Mov Disord; 2009 Sep; 24(12):1779-84. PubMed ID: 19562766
[TBL] [Abstract][Full Text] [Related]
18. Friedreich's ataxia: oxidative stress and cytoskeletal abnormalities.
Sparaco M; Gaeta LM; Santorelli FM; Passarelli C; Tozzi G; Bertini E; Simonati A; Scaravilli F; Taroni F; Duyckaerts C; Feleppa M; Piemonte F
J Neurol Sci; 2009 Dec; 287(1-2):111-8. PubMed ID: 19748629
[TBL] [Abstract][Full Text] [Related]
19. Characterizing gait, locomotor status, and disease severity in children and adolescents with Friedreich ataxia.
Croarkin E; Maring J; Pfalzer L; Harris-Love M; Siegel K; DiProspero N
J Neurol Phys Ther; 2009 Sep; 33(3):144-9. PubMed ID: 19809393
[TBL] [Abstract][Full Text] [Related]
20. Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease.
Schapira A; Lodi R
Methods Mol Biol; 2004; 277():293-307. PubMed ID: 15201464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
